BRPI0800485B8 - recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method - Google Patents
recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination methodInfo
- Publication number
- BRPI0800485B8 BRPI0800485B8 BRPI0800485A BRPI0800485A BRPI0800485B8 BR PI0800485 B8 BRPI0800485 B8 BR PI0800485B8 BR PI0800485 A BRPI0800485 A BR PI0800485A BR PI0800485 A BRPI0800485 A BR PI0800485A BR PI0800485 B8 BRPI0800485 B8 BR PI0800485B8
- Authority
- BR
- Brazil
- Prior art keywords
- leishmaniasis
- viral vectors
- recombinant viral
- vaccine composition
- vaccination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
vetores virais recombinantes, composição vacinal para leishmaniose e método profilático/terapêutico de vacinação para leishmaniose. a presente invenção diz respeito a vetores virais recombinantes que expressam o antígeno a2 de leishmania e composições vacinais úteis para serem utilizadas como vacina contra leishmaniose. a invenção ainda revela um método de vacinação dose-reforço (prime-boost) que utiliza vetores adenovirais e poxvirais para a imunização de mamíferos contra leishmaniose. tal método permite a distinção sorológica entre indivíduos vacinados e infectados por meio de testes de elisa ou imunofluorescência convencionais empregando antígenos de formas promastigotas de leishmania.recombinant viral vectors, vaccine composition for leishmaniasis and prophylactic/therapeutic method of vaccination for leishmaniasis. the present invention relates to recombinant viral vectors expressing the a2 antigen of leishmania and vaccine compositions useful to be used as a vaccine against leishmaniasis. the invention further discloses a dose-boost (prime-boost) vaccination method that uses adenoviral and poxviral vectors to immunize mammals against leishmaniasis. such method allows the serological distinction between vaccinated and infected individuals by means of conventional elisa or immunofluorescence tests using antigens from promastigote forms of leishmania.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0800485A BRPI0800485B8 (en) | 2008-01-17 | 2008-01-17 | recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method |
MX2010007876A MX2010007876A (en) | 2008-01-17 | 2009-01-16 | Recombinant viral vectors and vaccine composition for leishmaniasis. |
PCT/BR2009/000014 WO2009089605A1 (en) | 2008-01-17 | 2009-01-16 | Recombinant viral vectors and vaccine composition for leishmaniasis |
CN201710930134.7A CN108014330A (en) | 2008-01-17 | 2009-01-16 | Recombinant viral vector and vaccine combination for leishmaniasis |
CN200980105562XA CN102036681A (en) | 2008-01-17 | 2009-01-16 | Recombinant viral vectors and vaccine composition for leishmaniasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0800485A BRPI0800485B8 (en) | 2008-01-17 | 2008-01-17 | recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0800485A2 BRPI0800485A2 (en) | 2009-09-01 |
BRPI0800485A8 BRPI0800485A8 (en) | 2018-04-17 |
BRPI0800485B1 BRPI0800485B1 (en) | 2021-03-02 |
BRPI0800485B8 true BRPI0800485B8 (en) | 2021-05-25 |
Family
ID=40885010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0800485A BRPI0800485B8 (en) | 2008-01-17 | 2008-01-17 | recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method |
Country Status (4)
Country | Link |
---|---|
CN (2) | CN108014330A (en) |
BR (1) | BRPI0800485B8 (en) |
MX (1) | MX2010007876A (en) |
WO (1) | WO2009089605A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2795149B2 (en) | 2020-06-08 | 2022-07-04 | Univ Madrid Complutense | SYNTHETIC MULTIEPITOPIC CHIMERA AS A VACCINE AND TREATMENT AGAINST LEISHMANIOSIS IN MAMMALS |
CN113337542A (en) * | 2021-06-10 | 2021-09-03 | 山西大学 | Human replication-defective recombinant adenovirus vector for efficiently expressing Leishmania PEPCK |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09502091A (en) * | 1993-09-03 | 1997-03-04 | マックギル ユニヴァーシティー | Leishmania genes and proteins that are specifically expressed |
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6638517B2 (en) * | 1995-09-22 | 2003-10-28 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
ES2109189B1 (en) * | 1996-03-14 | 1998-05-16 | Iberica Cyanamid | VECTORS BASED ON RECOMBINANT DEFECTIVE VIRAL GENOMES AND THEIR USE IN THE FORMULATION OF VACCINES. |
WO2002078735A2 (en) * | 2001-03-29 | 2002-10-10 | Mcgill University | Leishmania vaccines |
EP1771571A2 (en) * | 2004-07-30 | 2007-04-11 | Targeted Genetics Corporation | Recombinant aav based vaccine methods |
-
2008
- 2008-01-17 BR BRPI0800485A patent/BRPI0800485B8/en active IP Right Grant
-
2009
- 2009-01-16 CN CN201710930134.7A patent/CN108014330A/en active Pending
- 2009-01-16 WO PCT/BR2009/000014 patent/WO2009089605A1/en active Application Filing
- 2009-01-16 CN CN200980105562XA patent/CN102036681A/en active Pending
- 2009-01-16 MX MX2010007876A patent/MX2010007876A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0800485A8 (en) | 2018-04-17 |
CN108014330A (en) | 2018-05-11 |
BRPI0800485B1 (en) | 2021-03-02 |
WO2009089605A1 (en) | 2009-07-23 |
BRPI0800485A2 (en) | 2009-09-01 |
CN102036681A (en) | 2011-04-27 |
MX2010007876A (en) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201291105A1 (en) | ORAL VACCINE CONTAINING ANTIGEN AND AGONIST OF TOLL-LIKE RECEPTOR | |
EA200701786A1 (en) | POLYVALENT ANTIGRIPOSE IMMUNOGENOUS COMPOSITION | |
EA200701128A1 (en) | Recombinant strains of BCG, possessing enhanced ability to release from endosomes. | |
BR112014011229A2 (en) | compositions and methods for the treatment of cytomegalovirus | |
BRPI0518146A (en) | parts kit, use of a recombinant defective adenovirus in replication, and method of vaccinating a mammal for malaria infection | |
ATE527281T1 (en) | VACCINES AGAINST AIDS COMPRISING CMV/R NUCLEIC ACID CONSTRUCTS | |
BR112015009070A2 (en) | fusion protein or antigen cocktail; use of a fusion protein or cocktail of antigens; vaccine; and method for immunizing an animal, including a human, against tuberculosis caused by virulent microbacteria | |
UY31285A1 (en) | VACCINES | |
WO2011109511A3 (en) | Novel hiv-1 envelope glycoprotein | |
CO6210756A2 (en) | THE TIMICA CANINA STROMAL LYMPHOPOYETINE PROTEIN AND USES OF THE SAME | |
AR093712A1 (en) | IMMUNOGEN COMPOSITION, VACCINE, USE AND PROCEDURE FOR PREVENTION OR TREATMENT | |
BRPI1007721B1 (en) | vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66 | |
CL2017003224A1 (en) | Vaccine against foot-and-mouth disease virus (fmdv) of recombinant modified vaccinia ankara virus (mva) | |
WO2006050219A3 (en) | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies | |
NO20074855L (en) | Use of a modified pox virus for the rapid induction of immunity to a pox virus or other infectious agents | |
UA110024C2 (en) | VACCINE VECTOR AND METHOD OF IMMUNE IMPROVEMENT | |
CO2019000214A2 (en) | Vaccine against infectious bronchitis virus | |
WO2011057254A3 (en) | Simian adenoviral vector-based vaccines | |
PE20081687A1 (en) | FUSION PROTEIN | |
MX2016001695A (en) | Combination immunogenic compositions. | |
BR112012029633A8 (en) | PARAPOXVIRUS VECTORS CONTAINING RABBIT VIRUS ANTIGEN. | |
BRPI0800485B8 (en) | recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method | |
MX2019007924A (en) | Influenza vaccines. | |
AR093530A1 (en) | VACCINATION ASSISTANT, PREPARATION, AND VACCINES CONTAINING IT | |
EA201200538A1 (en) | ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B03H | Publication of an application: rectification [chapter 3.8 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06V | Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette] | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |